Keurig Dr Pepper impresses investors with a 3.5% year-on-year sales surge to $3.47 billion in Q1 FY24, outperforming analyst predictions. Notably, U.S. Refreshment Beverages lead the growth trajectory with a 4.3% rise to $2.1 billion.
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitationNorway is a single-payer national health insurance systemLIFEHAB is targeting enrollment
Nvidia's transition from a gaming giant to an AI leader, especially during the early days of the pandemic, has been a significant driver of its stock's growth.
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal 2024 outlook: low double-digit revenue and EPS growth.
Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage diabetes, pre-diabetes, blood pressure, weight and taking a GLP-1NEW YORK, April 25, 2024
Novel Supplement Shown to Address Signs and Symptoms of Dry Eyes, All Primary Endpoints AchievedBausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live
Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval